Remove topic policy-regulation
article thumbnail

How do Healthcare AI Developers (and Buyers) Stay Ahead of the Regulatory Curve?

Nixon Gwilt Law

No centralized framework for the regulation of artificial intelligence in the United States currently exists. HIPAA is the pantheon of healthcare data privacy regulation in the U.S. Federal Trade Commission (FTC) The FTC is the country’s consumer watchdog, enforcing antitrust policy and promoting consumer protection.

article thumbnail

Kite and Daiichi Sankyo update cell therapy licensing agreement

Pharmaceutical Technology

Regulators in Japan have granted approval for the manufacturing plant of Kite in El Segundo, California, US, to produce Yescarta for the Japanese market. Topic sponsors are not involved in the creation of editorial content. The delivery of the product is anticipated to begin early next year. Free Whitepaper.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

ISPOR Announces Real-World Evidence Summit 2023

PM360

The Summit is a collaboration between ISPOR, the International Society for Pharmacoepidemiology (ISPE), and the Duke-Margolis Center for Health Policy. Speakers include: Moderator: Richard Willke, PhD; ISPOR; Lawrenceville, NJ, USA Adam Aten, MPH, MSc; Duke-Margolis Center for Health Policy; Washington, DC, USA C.

article thumbnail

US FDA approves Krystal Biotech’s Vyjuvek for DEB

Pharmaceutical Technology

Vyjuvek is a non-invasive, topical, re-dosable gene therapy that delivers functional human COL7A1 gene copies to offer wound healing. We offer our sincere gratitude to DEB patients, caregivers, investigators, US regulators and our employees who made this approval possible.

FDA 52
article thumbnail

Rocket Pharmaceuticals’ RP-A601 receives FDA designations

Pharmaceutical Technology

Rocket Pharmaceuticals stated that the fast-track designation enables increased communication with the regulator across the development cycle of the gene therapy. Topic sponsors are not involved in the creation of editorial content. An estimated 50,000 people in Europe and the US are affected by PKP2-ACM.

article thumbnail

Three regulators accept Bristol Myers’ applications for myeloma therapy

Pharmaceutical Technology

Three regulators in different jurisdictions have accepted Bristol Myers Squibb’s applications for Abecma (idecabtagene vicleucel) for earlier use to treat triple-class exposed relapsed and/or refractory multiple myeloma in adult patients. Topic sponsors are not involved in the creation of editorial content.

article thumbnail

Generative AI’s potential to speed delivery of improved patient outcomes

Clarivate

As when any new technology appears on the horizon, a tremendous amount of overheated hyperbole has dominated coverage of the topic in the months since. Regulatory asymmetry: Laws governing generative AI vary widely across markets and are evolving rapidly as regulators scramble to address this emerging technology.